Replies to post #107903 on Anavex Life Sciences Corp (AVXL)

[powerwalker]

T, I don't believe 2-73 was involved in any part of the Biogen failed test that Xena reported. Below is a quote from her post #107836.

The phase 2 study evaluated the impact of opicinumab in 418 participants with relapsing forms of MS over 72 weeks

.

Biogen and Anavex entered the MTA 8+ months ago, well after the opicinumab trial began.

[XenaLives]

I don't think that they had time to include 2-73 in the failed trial.

I would expect them to announce preclinical results that were superior to the last results of the drug and the way they expect 2-73 to make their drug work better and another phase 2.

Of course that would have to come with a licensing agreement. :)